Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.66 - $1.29 $68,438 - $133,765
-103,694 Reduced 53.0%
91,953 $68,000
Q4 2022

Feb 13, 2023

BUY
$1.1 - $2.45 $1,046 - $2,329
951 Added 0.49%
195,647 $242,000
Q3 2022

Nov 14, 2022

SELL
$1.96 - $3.32 $18,620 - $31,540
-9,500 Reduced 4.65%
194,696 $401,000
Q2 2022

Aug 11, 2022

BUY
$2.27 - $4.86 $7,677 - $16,436
3,382 Added 1.68%
204,196 $566,000
Q1 2022

May 13, 2022

SELL
$3.69 - $5.65 $26,940 - $41,250
-7,301 Reduced 3.51%
200,814 $878,000
Q4 2021

Feb 11, 2022

BUY
$5.37 - $7.07 $23,552 - $31,009
4,386 Added 2.15%
208,115 $1.15 Million
Q3 2021

Nov 04, 2021

SELL
$5.54 - $7.51 $271,753 - $368,388
-49,053 Reduced 19.41%
203,729 $1.26 Million
Q2 2021

Aug 11, 2021

BUY
$7.78 - $11.4 $1.36 Million - $1.99 Million
174,981 Added 224.91%
252,782 $2.15 Million
Q1 2021

May 13, 2021

BUY
$5.12 - $8.48 $61,009 - $101,047
11,916 Added 18.09%
77,801 $615,000
Q4 2020

Feb 16, 2021

SELL
$3.16 - $7.03 $3.59 Million - $7.98 Million
-1,134,796 Reduced 94.51%
65,885 $384,000
Q3 2020

Nov 12, 2020

BUY
$3.26 - $4.73 $3.79 Million - $5.5 Million
1,163,415 Added 3121.92%
1,200,681 $4.07 Million
Q2 2020

Aug 13, 2020

BUY
$1.58 - $4.63 $19,754 - $57,888
12,503 Added 50.49%
37,266 $172,000
Q1 2020

May 14, 2020

SELL
$1.44 - $3.02 $2,148 - $4,505
-1,492 Reduced 5.68%
24,763 $40,000
Q4 2019

Feb 14, 2020

BUY
$2.25 - $3.07 $19,793 - $27,006
8,797 Added 50.39%
26,255 $71,000
Q3 2019

Nov 14, 2019

SELL
$2.67 - $3.65 $134,306 - $183,602
-50,302 Reduced 74.24%
17,458 $50,000
Q2 2019

Aug 14, 2019

BUY
$2.6 - $4.21 $8,499 - $13,762
3,269 Added 5.07%
67,760 $194,000
Q1 2019

May 15, 2019

BUY
$3.05 - $4.34 $47,021 - $66,909
15,417 Added 31.42%
64,491 $270,000
Q4 2018

Feb 14, 2019

BUY
$2.82 - $4.67 $132,483 - $219,396
46,980 Added 2243.55%
49,074 $152,000
Q3 2018

Nov 14, 2018

BUY
$1.45 - $6.15 $2,856 - $12,115
1,970 Added 1588.71%
2,094 $8,000
Q2 2018

Aug 14, 2018

SELL
$1.65 - $2.5 $125,965 - $190,857
-76,343 Reduced 99.84%
124 $0
Q1 2018

May 15, 2018

BUY
$1.25 - $2.65 $58,458 - $123,932
46,767 Added 157.46%
76,467 $141,000
Q4 2017

Feb 14, 2018

SELL
$1.23 - $2.3 $60,640 - $113,392
-49,301 Reduced 62.41%
29,700 $38,000
Q3 2017

Nov 14, 2017

BUY
$1.95 - $2.25 $154,051 - $177,752
79,001
79,001 $177,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.